Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6857 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-27 (biospace.com)
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal -
Company Board Concludes the Proposal Significantly Undervalues Sage and Believes it is Not in the Best Interest of Shareholders
Read more
2024-10-02 (lifescienceleader.com)
Annovis Bio: Against The Grain In Alzheimer's Disease
From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s independent-minded approach to...
Read more
2024-09-26 (life-sciences-usa.com)
Organon–Karp D: management, 202409– promoted to EVP Corporate Development before Chief Business Development Officer before Biogen + Pfizer
Life Sciences Business Intelligence Web Portal for North America, Europe and Israel
Read more
2024-09-12 (tipranks.com)
Biogen Enhances Board with Medical Experts’ Appointment
Biogen ( ($BIIB) ) has provided an update. Biogen Inc. has expanded its Board of Directors with the appointment of Dr. Lloyd Minor and Prof Sir Menelas Pangalos, ef...
Read more
2024-09-11 (pharmafile.com)
George Scangos to step down as Biogen CEO
In a surprising move, Biogen used the publishing of some promising second quarter results to announce the departure of CEO George Scangos, with the search for his successor set to begin immediately.
Read more
2024-02-08 (marketbeat.com)
Massachusetts Financial Services Co. MA Increases Holdings in Biogen Inc. (NASDAQ:BIIB)
Massachusetts Financial Services Co. MA raised its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 204.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 446,602 shares of the biotechnology company's
Read more
2024-02-07 (bioprocessintl.com)
eBooks
BioProcess International is part of the Informa Connect Division of Informa PLC
Read more
2023-11-17 (finanznachrichten.de)
Biogen at the annual meeting of the Society for Pediatric Neurology: Progress in rare diseases such as spinal muscular atrophy and Friedreich's ataxia
Dortmund (ots) - Biogen Germany, a leading provider of innovative therapies for neuromuscular and rare diseases, will be at GNP, the society's 48th annual meeting, from November 16th to 18th
Read more
2023-11-08 (endpts.com)
Biogen CEO seeks collaborations to expand pipeline as postpartum depression, Alzheimer's and ALS drugs ...
Biogen CEO Chris Viehbacher said the famed Boston biotech is ready to do
Read more
2023-06-26 (reuters.com)
Biogen shareholders back Susan Langer as director
Biogen shareholders elected former company executive Susan Langer as a director on Monday, weeks after her romantic partner, Alex Denner, vacated the seat and the board nominated her to replace him.
Read more
2023-06-13 (statnews.com)
Biogen’s boardroom scandal saddles CEO with first crisis
This was supposed to be the new Biogen. Then came another boardroom controversy.
Read more
2023-06-13 (bostonglobe.com)
Biogen nominates departing board member’s live-in partner as his replacement - The Boston Globe
Susan Langer’s nomination to the board, and Biogen’s failure to disclose her relationship with a current director, is certain to raise questions about the company’s corporate governance practices.
Read more
Used by 100+ compliance teams and analysts